Skip to main content

Table 2 Biomarkers determination

From: Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

 

Primary tumor (n = 70)

Metastases (n = 49)

Clinical practicea (n = 102)

No. (%)

No. (%)

No. (%)

ER status

  < 1%

3 (4.3)

0

2 (2.0)

  ≥ 1%

65 (92.9)

49 (100)

100 (98.0)

 Unknown

2 (2.8)

0

0

PgR status

  < 1%

10 (14.3)

12 (24.5)

22 (21.6)

  ≥ 1%

58 (82.9)

37 (75.5)

80 (78.4)

 Unknown

2 (2.8)

0

0

Ki67 status

  < 20%

39 (55.7)

30 (61.2)

63 (61.8)

  ≥ 20%

27 (38.6)

17 (34.7)

38 (37.2)

 Unknown

4 (5.7)

2 (4.1)

1 (1)

HER2 status

 Negative

57 (81.4)

41 (83.7)

88 (86.3)

 Positive

10 (14.3)

7 (14.3)

14 (13.7)

 Unknown

3 (4.3)

1 (2)

0

AR status

  < 1%

5 (7.1)

12 (24.5)

17 (16.7)

  ≥ 1%

65 (92.9)

37 (75.5)

85 (83.3)

  < 10%

7 (10.0)

19 (38.8)

26 (25.5)

  ≥ 10%

63 (90.0)

30 (61.2)

76 (74.5)

  1. Abbreviation: ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
  2. abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed